Purigen Biosystems, Inc.

Newer Older
SHARE:

Purigen Biosystems Signs Exclusive Distribution Agreement with Bonsai Lab to Strengthen Commercial Presence Across European Union

Automated Ionic® Purification System is CE Mark certified and now available to clinical and oncology researchers in Spain and Portugal

Pleasanton, Calif. – February 10, 2022Purigen Biosystems, Inc., a leading provider of next-generation technologies for extracting and purifying nucleic acids from biological samples, today announced a new distribution agreement with Bonsai Lab. Under the terms of the agreement, Bonsai Lab has received exclusive rights to distribute, service, and support Purigen’s automated Ionic® Purification System and microfluidic kits in Portugal and Spain. Clinical and oncology researchers in these countries are now able to purchase and use the automated system, which received a CE (Conformité Européene) marking in May 2021, to extract higher yields of purified DNA and RNA from challenging samples in one hour with minimal hands-on time.

“Bonsai Lab is proud to bring innovative genomic technologies from around the world to our customers in Spain and Portugal,” said Rafael Calderón, Managing Director at Bonsai Lab. “Purigen’s best-in-class purification tools will allow our clients to simplify their sample prep workflows and generate high yields of DNA or RNA from different types of biological samples for next-generation sequencing, qPCR, and other analysis protocols.”

Launched in the US market in 2019, the small benchtop Ionic Purification System enables the automated extraction of nucleic acids with dramatically increased yield and quality from a wide range of sample types, including cultured or sorted cells and formalin-fixed, paraffin-embedded (FFPE) tissues. Biological samples are gently lysed and then loaded into the Ionic® Fluidics Chip. The system then applies an electrical field to the chip and the nucleic acids are isolated in their native form using the company’s core isotachophoresis (ITP) technology. Since the nucleic acids are not bound or stripped from fixed surfaces, nucleic acid loss and fragmentation are minimized while purification-induced bias is eliminated. The simplified workflow requires minimal hands-on time and ensures that sufficient amounts of nucleic acid are available for all downstream analysis techniques, such as next-generation sequencing and qPCR. For more information, please visit www.purigenbio.com/products/ionic-system.

“Bonsai Lab is the premier next-generation genomics technology provider in Spain and Portugal,” said Aziz Mustafa, PhD, Senior Director of European Sales and Business Development for Purigen Biosystems. “This agreement offers a great opportunity to expand our commercial business in Europe and to solidify our position as a leading provider of nucleic acid extraction and purification technologies.”


About Bonsai Lab
Bonsai Lab is a specialized distributor of innovative next-generation genomics solutions, operating in Spain and Portugal. By focusing on delivering high-quality solutions and providing best-in-class support to customers, Bonsai Lab represents “the perfect link between researchers and manufacturers of the best analytical solutions.” For more information, visit www.bonsailab.com.

About Purigen Biosystems
Purigen Biosystems is redefining nucleic acid sample preparation with an innovative platform based on the highly efficient isotachophoresis technology invented by Juan Santiago, PhD, and his team at Stanford University. Purigen’s automated benchtop instrument and accompanying microfluidic chip purify nucleic acid samples from a wide variety of sources, including minute or otherwise challenging cancer samples. The purified nucleic acids are then immediately compatible with a wide range of downstream detection methods, including next-generation sequencing, PCR, and other genomic tests. For more information, visit www.purigenbio.com.

Ionic is a registered trademark of Purigen Biosystems, Inc. All other trademarks are the property of their respective owners. All products described herein are intended FOR RESEARCH USE ONLY and NOT FOR USE IN DIAGNOSTIC PROCEDURES.


MEDIA CONTACT
Purigen Biosystems
Andrew Noble
415-722-2129
andrew@bioscribe.com

Bonsai Lab
Elvis Pérez Mba, Product Manager
+34 916 629 877
info@bonsailab.com